CoChat

Anti‐Emetic Therapy in Cancer Chemotherapy: Current Status

Open access
Herrstedt, Jørn, Dombernowsky, Per · 2007 · Basic & Clinical Pharmacology & Toxicology
Cited by 75

The DOI matches its Crossref record.

Abstract

Nausea and vomiting are ranked as the most severe side effects to chemotherapy by cancer patients. Twenty years ago, treatment of nausea and vomiting from chemotherapy only had moderate effect and often unpleasant side effects. The drugs used included dopamine 2‐receptor antagonists and corticosteroids alone or combined. This review summarizes the development of anti‐emetic therapy, but will focus on the importance of two new classes of anti‐emetics: the serotonin 3‐ and the neurokinin 1‐receptor antagonists. Furthermore, evidence‐based guidelines for the treatment of chemotherapy‐induced nausea and vomiting will be given. The serotonin 3‐receptor antagonists, the first group of drugs developed specifically as anti‐emetics, have significantly improved the prophylaxis of chemotherapy‐induced emesis especially in combination with a corticosteroid. The improvement in the prophylaxis of nausea with this combination is however modest. A new group of anti‐emetics, the neurokinin 1‐receptor antagonists, has now been developed, and the first drug, aprepitant, was marketed in 2003. Aprepitant increases the effect of a serotonin 3‐receptor antagonist plus a corticosteroid against acute emesis induced by highly or moderately emetogenic chemotherapy and aprepitant is also active in the protection against delayed emesis. The importance of drug–drug interactions with anti‐emetics and other drugs, especially cytotoxins, through their competition for cytochrome P450 enzymes, have been studied. At present, there is no evidence that such interactions are of major clinical importance. Evidence‐based clinical guidelines are now available and regularly updated, but unfortunately clinical implementation is slow. Recommendations for some types of chemotherapy‐induced emesis such as delayed emesis, is based on a low level of evidence. Furthermore, the majority of clinical trials include highly selected groups of patients not permitting definite conclusions for other and more heterogeneous patient groups. Development of new anti‐emetics with other mechanisms of action is awaited with interest.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-7843.2007.00122.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 75

Metadata

Authors
Herrstedt, J., & Dombernowsky, P.
Venue
Basic & Clinical Pharmacology & Toxicology
Publisher
Wiley
Published
2007-08-13
Volume
101
Issue
3
Pages
143-150
ISSN
  • 1742-7835 (ISSN-L)
  • 1742-7843
OpenAlex
W2061507966
Cited by
75
References
0
FWCI
3.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti‐Emetic Therapy in Cancer Chemotherapy: Current Status. https://app.cochat.ai/papers/10.1111/j.1742-7843.2007.00122.x
The paper
Herrstedt, J., & Dombernowsky, P. (2007). Anti‐Emetic Therapy in Cancer Chemotherapy: Current Status. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/j.1742-7843.2007.00122.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.